BCL11A overexpression predicts survival and relapse in non-small cell lung cancer and is modulated by microRNA-30a and gene amplification by Ben-yuan Jiang et al.
Jiang et al. Molecular Cancer 2013, 12:61
http://www.molecular-cancer.com/content/12/1/61RESEARCH Open AccessBCL11A overexpression predicts survival and
relapse in non-small cell lung cancer and is
modulated by microRNA-30a and gene
amplification
Ben-yuan Jiang1,3†, Xu-chao Zhang1,2†, Jian Su1,2, Wei Meng1,2, Xue-ning Yang1, Jin-ji Yang1, Qing Zhou1,
Zhi-yong Chen1, Zhi-hong Chen1,2, Zhi Xie1,2, Shi-liang Chen1,2 and Yi-long Wu1*Abstract
Background: Aberrant activation of the proto-oncogene B-cell lymphoma/leukemia 11A (BCL11A) has been
implicated in the pathogenesis of leukemia and lymphoma. However, the clinical significance of BCL11A in
non-small cell lung cancer (NSCLC) remains unknown.
Results: We examined BCL11A expression at the protein and mRNA levels in a cohort (n = 114) of NSCLC patients
and assessed the relationship between BCL11A expression and clinicopathological parameters. Data from
array-based Comparative Genomic Hybridization (aCGH) and microRNA transfection experiments were integrated to
explore the potential mechanisms of abnormal BCL11A activation in NSCLC. Compared to adjacent non-cancerous
lung tissues, BCL11A expression levels were specifically upregulated in NSCLC tissues at both the mRNA (t = 9.81,
P < 0.001) and protein levels. BCL11A protein levels were higher in patients with squamous histology (χ2 = 15.81,
P = 0.001), smokers (χ2 = 8.92, P = 0.004), patients with no lymph node involvement (χ2 = 5.14, P = 0.029), and
patients with early stage disease (χ2 = 3.91, P = 0.048). A multivariate analysis demonstrated that in early stage
NSCLC (IA–IIB), BCL11A was not only an independent prognostic factor for disease-free survival (hazards ratio [HR]
0.24, 95% confidence interval [CI] 0.12-0.50, P < 0.001), but also for overall survival (HR = 0.23, 95% CI 0.09-0.61, P =
0.003). The average BCL11A expression level was much higher in SCC samples with amplifications than in those
without amplifications (t = 3.30, P = 0.023). Assessing functionality via an in vitro luciferase reporter system and
western blotting, we found that the BCL11A protein was a target of miR-30a.
Conclusions: Our results demonstrated that proto-oncogene BCL11A activation induced by miR-30a and gene
amplification may be a potential diagnostic and prognostic biomarker for effective management of this disease.
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Lung cancer, especially non-small cell lung cancer
(NSCLC), is the leading cause of cancer-associated
deaths in China and worldwide [1]. Despite advances in
early diagnosis and standard treatment, the prognosis of
NSCLC patients remains poor, with 5-year survival less
than 15% [2]. A better understanding of the molecular* Correspondence: syylwu@live.cn
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reproduction in any medium, provided the ormechanisms underlying lung cancer is needed for more
efficient cancer management [1,3]. Molecular epidemio-
logical studies have provided evidence that multiple
mechanisms, including activation of oncogenes (EGFR,
KRAS), inactivation of tumor suppressors (TP53), and
dysregulation of DNA repair genes (CHEK1), contribute
to early stage lung cancer development [1,4,5]; however,
these molecular alterations are not enough to explain
the heterogeneity of NSCLC. Identification of relevant
molecular alterations occurring at early stage disease
has the potential to identify diagnostic or predictivetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tailored treatments to decrease the overall mortality of
this disease.
The B-cell lymphoma/leukemia 11A (BCL11A) gene
encodes a Krüppel zinc-finger transcription factor, which
has been shown to be essential for pre-B-cell develop-
ment, thymocyte maturation, and globin switching [6,7].
This gene was first identified in a rare t (2;14) (p16;q32.3)
translocation in aggressive B-cell chronic lymphocytic
leukemia and was regarded as a candidate oncogene, as it
was often co-amplified with the REL proto-oncogene in
non-Hodgkin’s lymphoma and in classical Hodgkin’s
lymphoma [8,9]. Furthermore, retroviral integration into
the BCL11A locus has been shown to activate its expres-
sion, transform NIH 3T3 cells, and induce myeloid
leukemia in mice [6,10].
BCL11A involvement in solid tumors has been rarely
reported, and whether deregulation of BCL11A expres-
sion occurs in NSCLC remains unclear. To address
BCL11A expression and its potential clinical relevance
in detail, we determined BCL11A expression at both the
mRNA and protein levels and determined its prognostic
significance by correlating BCL11A expression with
clinicopathologic features and survival in NSCLC pa-
tients. We also investigated the mechanisms underlying
BCL11A activation in NSCLC.
Results
BCL11A mRNA is specifically upregulated in NSCLC tissues
Based on our gene expression profiling data, we found that
BCL11A was differentially expressed between cancer and
adjacent non-cancerous tissues, with 3.06-fold upregulation
in cancer tissues (t = 9.81, P < 0.001). Whether comparing
between all cancer and adjacent tissues or just between
paired cancerous and non-cancerous tissues, BCL11A
mRNA was upregulated in cancer tissues (Figure 1A, B).
Furthermore, when BCL11A expression was analysed
according to different histological subtypes, BCL11A
mRNA was upregulated mainly in squamous cell carcin-
oma (SCC) (Figure 1C, D). A correlation analysis was
performed to explore whether BCL11A mRNA levels
were related to clinicopathological variables in patients
with NSCLC. BCL11A mRNA levels had no relationship
with age, sex, or histology, but they did correlate with
lymph node status and disease stage. Decreased
BCL11A mRNA levels were associated with lymph node
involvement (χ2 = 6.17, P = 0.013) and advanced stage
(χ2 = 4.21, P = 0.040) (Table 1).
BCL11A protein is specifically upregulated in NSCLC
tissues
Expression of BCL11A at the protein level was also inves-
tigated in 113 NSCLC and 25 adjacent non-cancerous
lung tissues by immunohistochemistry. BCL11A proteinstaining was not found in the 25 adjacent lung tissues
(Figure 2). Statistical analysis revealed no significant corre-
lations between BCL11A protein level and age, sex, or per-
formance status. However, BCL11A expression level was
strongly associated with histology (χ2 = 15.81, P = 0.001),
smoking status (χ2 = 8.92, P = 0.004), lymph node status
(χ2 = 5.14, P = 0.029), and disease stage (χ2 = 3.91, P =
0.048) (Table 1).BCL11A protein level correlates with disease-free survival
(DFS) and overall survival (OS) in early stage squamous
carcinoma NSCLC patients
For all 113 patients subjected to immunohistochemical
staining for BCL11A, 68 (59.2%) had low BCL11A ex-
pression and 45 (40.8%) had high BCL11A expression.
High BCL11A expression was predictive of better
overall survival (OS) (log rank χ2 = 3.79, P = 0.05) and
better disease-free survival (DFS) (log rank χ2 = 12.70,
P = 0.0004) (Figure 3A, B). The median DFS of patients
with low BCL11A expression levels was 23.0 ± 4.5
months, but in the high BCL11A expression group, only
32.6% of patients relapsed at the endpoint of follow-up.
The multivariate survival analysis indicated that BCL11A
expression level was an independent marker of DFS in
patients with NSCLC (hazards ratio [HR] 0.40, 95% confi-
dence interval [CI] 0.22–0.72, P = 0.002). Furthermore, we
found that in a subgroup of patients with early stage can-
cer (IA–IIB) (Table 2), and in particular early SCC
(Table 3), BCL11A was not only a significant prognostic
factor for DFS (HR 0.18, 95% CI 0.05–0.66, P = 0.01), but
also for OS (HR 0.17, 95% CI 0.06–0.50, P = 0.001)
(Figure 3C-F). No correlations between BCL11A expres-
sion and DFS or OS were observed in advanced stage
(IIIA–IV) NSCLC patients (Additional file 1: Figure S1).BCL11A gene copy number gains in lung squamous
carcinoma
Ten probes targeting BCL11A on the Agilent aCGH chip
(A_16_P15674055, A_14_P129011, A_16_P15674243, A_
16_P00386603, A_16_P00386649 and A_14_P106886)
were used to determine the normalized logarithmic inten-
sity of BCL11A copy number changes. The average inten-
sity of the 10 probes for BCL11A in SCC was 0.35,
significantly higher than that in adenocarcinoma (0.03)
(t = 5.37, P = 0.0007). Log intensities >0.30 were consid-
ered indicative of gene amplification in aCGH analysis.
Thus, BCL11A was amplified in SCC, while in large-cell
carcinoma (LCC) (n = 11) the intensity was 0.23, indicating
no BCL11A gene amplification (Figure 4A). A significantly
higher average expression level was observed for BCL11A
in the SCC samples with amplifications as compared to



























































































































































































































































































































































































































































































































































































































Cacner tissues (25) Paired adjacent non-cancerous tissues (25) 
Figure 1 (See legend on next page.)
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Figure 1 BCL11A mRNA is upregulated in cancer tissues compared to adjacent non-cancerous tissues. Normalized intensity of BCL11A
expression was determined by Affymetrix® mRNA array and compared between (A) all 114 NSCLC cancer tissues and 53 adjacent non-cancerous
lung tissues; (B) 53 NSCLC cancer tissues and paired adjacent non-cancerous lung tissues; (C) 25 paired lung adenocarcinoma and adjacent lung
tissues; (D) 20 paired lung squamous carcinoma and adjacent lung tissues. BCL11A was specifically upregulated in NSCLC tissues, especially in
squamous cell lung carcinoma tissues.
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downregulated in NSCLC tissues
MicroRNAs (miRNAs) have gained considerable atten-
tion as regulators of gene expression [10], and they play
important roles in cellular differentiation and embryonic
stem cell development [11]. We postulated that they
may also play a role in modulating BCL11A expression.
In order to test whether miRNAs play a role in control-
ling BCL11A expression, we computationally identified
those that might contribute to BCL11A regulation. Since
it has been generally accepted that intersecting the re-
sults of multiple prediction algorithms can increase
specificity, we chose to intersect the results of theTable 1 Relationships between BCL11A expression and clinico
BCL11A mRNA expression (n = 114)
Parameter No. Low (%) High (%) P
Age
<60 yr 50 21 (42.0) 29 (58.0)
≥60 yr 64 27 (42.2) 37 (57.8)
Sex
Female 33 13 (39.4) 20 (60.6)
Male 81 35 (43.2) 46 (56.8)
Performance status
0 58 25 (43.1) 33 (56.9)
1–2 56 23 (41.1) 33 (58.9)
Smoking status
No 53 21 (39.6) 32 (60.4)
Yes 61 27 (44.3) 34 (55.7)
Histological type
AC 68 29 (42.6) 39 (57.4)
SCC 35 15 (42.9) 20 (57.1)
LCC 11 4 (36.4) 7 (63.6)
Tumor size
≤ 3.0 cm 63 29 (46.0) 34 (54.0)
> 3.0 cm 51 19 (37.3) 32 (62.7)
Lymph node status
N0 72 24 (33.3) 48 (66.7)
N1–2 42 24 (57.1) 18 (42.9)
Pathological stage
I–II 89 33 (37.1) 56 (62.9)
III–IV 25 15 (60.0) 10 (40.0)prediction programs PicTar (4-way), miRanda (miRBase),
and TargetScan [12–14]. Overall, only three miRNAs
were found by these programs to target BCL11A, including
miR-1, miR-135a, and miR-30a (Figure 5A). We intersected
these three miRNAs with results of microarray-based
miRNA expression profiles (data not shown) and found
that only miR-1 and miR-30a were downregulated in
NSCLC tissues. We further analyzed the expression of
these two microRNAs in 22 paired tissues of NSCLC
patients by TaqMan real-time PCR. As compared to ad-
jacent tissues, miR-30a and miR-1 were downregulated
by 3.9- and 12.1-fold in cancer tissues, respectively
(Figure 5B).pathological factors.
BCL11A protein expression (n = 113)
-value No. Low (%) High (%) P-value
0.984 0.325
70 44 (62.9) 26 (37.1)
43 23 (53.5) 20 (46.5)
0.708 0.133
36 25 (69.4) 11 (30.6)
77 42 (54.5) 35 (45.5)
0.826 0.399
56 31 (55.4) 25 (44.6)
57 36 (63.2) 21 (36.8)
0.617 0.003
56 41 (73.2) 15 (26.8)
57 26 (45.6) 31 (54.4)
0.921 0.001
68 50 (73.5) 18 (26.5)
36 12 (33.3) 24 (66.7)
9 5 (55.6) 4 (44.4)
0.345 0.124
59 39 (66.1) 20 (33.9)
54 28 (51.9) 26 (48.1)
0.013 0.023
72 37 (51.4) 35 (48.6)
41 30 (73.2) 11 (26.8)
0.040 0.048
88 48 (54.5) 40 (45.5)
25 19 (76.0) 6 (34.0)
Figure 2 Detection of BCL11A protein expression by immunohistochemical staining in cancer and adjacent tissues. Representative
images of (A) negative or (B) positive staining of BCL11A in adenocarcinoma cells and (C) negative staining in adjacent lung tissues. (D) A zoom-
in view of BCL11A expression in lung adenocarcinoma cells. Similarly, representative images of (E) negative or (F) positive staining of BCL11A in
lung squamous carcinoma cells and (G) negative staining in adjacent lung tissues. (H) A zoom-in view of BCL11A expression in lung squamous
cell carcinoma cells.
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After co-transfection of pmirGLO dual luciferase reporter
plasmids carrying the 3′-UTR sequence of BCL11A and
plasmids expressing miR-30a, miR-1, or a control miRNA
into A549 and NIH3T3 cells, firefly luciferase activity was
normalized to Renilla luciferase activity. Significantrepression was only seen in miR-30a-transfected cells, but
not in either miR-1- or control miRNA-transfected cells.
When the nucleotide acid sequence in the BCL11A 3′
UTR that was complementary to the “seed region” of
miR-30a was replaced, the repression effect was com-
pletely rescued (Figure 6A-C).
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Figure 3 Kaplan-Meier estimated overall survival and disease-free survival curves of NSCLC patients according to BCL11A protein level.
(A) Overall survival of all 113 NSCLC patients. (B) Disease-free survival of all 113 NSCLC patients. (C) Overall survival of 88 early stage NSCLC
patients. (D) Disease-free survival of 88 early stage NSCLC patients. (E) Overall survival of 31 patients with early stage squamous cell lung cancer.
(F) Disease-free survival of 31 early stage squamous cell lung cancer patients. P values were calculated by log rank tests.
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in vitro
Since the 3′UTR of BCL11A could be a target of miR-
30a, we tested whether 3′UTR binding by miR-30a
resulted in changes in BCL11A protein expression in
H460 and H520 cell lines. First, we performed an immu-
noblot analysis using a BCL11A-specific antibody. After
transfection with miRNAs, BCL11A protein expression
in the H520 cell line was repressed by miR-30a, but not
by miR-1 or control miRNA (Figure 6D). After transient
transfection with a plasmid expressing miR-30a, BCL11A
staining in H460 cells was significantly downregulated
compared to those transfected with control miRNA, asdetermined by immunofluorescence and confocal micros-
copy (Figure 6E).
Discussion
The current study investigated the role of the proto-
oncogene BCL11A (B-cell lymphoma/leukemia 11A) in
NSCLC. Our results demonstrated that BCL11A was
upregulated in clinical NSCLC tissue samples at both
transcriptional and translational levels. Statistical ana-
lyses demonstrated that BCL11A expression was associ-
ated strongly with lymph node status, disease stage, and
the survival of patients with NSCLC. Moreover, we also
observed some significant differences between BCL11A
Table 2 Multivariate Cox regression analysis of BCL11A







Age 1.07 (1.03–1.12) ≥ 60/< 60 0.002
Tumor size 1.29 (1.08–1.57) ≥ 3 cm/< 3 cm 0.007





2.46 (1.06–5.68) 1-2/0 0.036
BCL11A protein 0.27 (0.11–0.69) Higher/lower 0.006
Histological type 0.003
SCC# 0.16 (0.05–0.54) SCC/AC 0.003
LCC※ 0.10 (0.03–0.38) LCC/AC 0.001
DFS






BCL11A protein 0.25 (0.12–0.51) Higher/lower 0.001
#SCC vs. AC; ※LCC vs. AC.
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analysis found that patients with higher BCL11A expres-
sion had better outcomes. BCL11A protein was an inde-
pendent prognostic factor of disease-free survival and
overall survival for early stage patients (IA–IIB), espe-
cially for early stage squamous carcinoma patients.
The proto-oncogene BCL11A spans over 102 kb on
chromosome 2p16 and is implicated in several neo-
plasms [9,15]. Its sequence is phylogenetically con-
served and codes for a zinc-finger protein with an
unusual C2HC zinc finger at the N-terminus and six
other Krüppel-like C2H2 zinc fingers near the C-
terminus [10]. BCL11A was reported to show restricted
expression in fetal liver, bone marrow, lymphoid, and
brain tissue [16,17], but our results clearly demon-
strated that the proto-oncogene BCL11A was actively
expressed in NSCLC. This phenomenon suggested that
abnormal activation of the proto-oncogene BCL11A
might contribute to tumorigenesis of NSCLC, although
the details of its function have not yet to be clarified.Table 3 Multivariate Cox regression analysis of BCL11A








Tumor size 1.38 (1.00–1.91) ≥ 3 cm/< 3 cm 0.049
BCL11A protein 0.18 (0.05–0.66) Higher/lower 0.010
DFS
BCL11A protein 0.17 (0.06–0.50) Higher/lower 0.001BCL11A can bind to 5′-GGCCGG-3′ DNA motifs with
high affinity, and can promote the deacetylation of his-
tone H3/H4 associated with the promoter reigons of
mammalian target genes, thereby causing transcrip-
tional repression [15,18]. A previous study reported that
enhanced BCL11A expression could repress P21 induc-
tion, which correlated with reduced colony formation
and cell cycle arrest of leukemic cells [19]. Yin et al. also
reported that BCL11A acts as an oncogene and causes
leukemia in the absence of NF1 in mice, perhaps
through suppression of P21 induction and thus promo-
tion of cell growth [20]. As is well known, the NF1 sup-
pressor gene is also frequently inactivated in NSCLC
[21]. Whether the same event occurs in NSCLC tumori-
genesis remains unclear. Apart from transcriptional
repression, Yu et al. found that BCL11A can also
upregulate expression of BCL2, BCL2-xL, and MDM2
which inhibits P53 activities [22]. These molecular alter-
ations occur frequently in solid tumors including lung
cancer. Therefore, BCL11A may contribute to tumori-
genesis through effects on apoptosis, the cell cycle, and
DNA damage repair, but the exact mechanisms warrant
further investigation.
When compared to patients with advanced stage
NSCLC and lymph node involvement, BCL11A expres-
sion was much higher in patients with early stage cancer
and no lymph node involvement, which suggests that ac-
tivation of the BCL11A proto-oncogene might be an
early stage event in NSCLC. We performed a survival
analysis and found that high BCL11A expression corre-
lated with better survival and DFS, results similar to
previous data on lymphoma. Pulford et al. performed
immunolabelling studies on 107 cases of DLBCL (diffuse
large B-cell lymphoma) and showed a trend towards
poorer survival in patients with BCL11A-xL-negative tu-
mors [23]. Recently, it was reported that BCL11A was
amplified in lung squamous cell carcinoma (SCC), and
this amplification was significantly more frequent in
SCC samples of NSCLC patients without metastases
[24]. In our study, BCL11A protein level was a protect-
ive factor for both DFS and OS of early stage NSCLC
patients, especially for early stage SCC. Therefore, one
wonders whether BCL11A inhibits cancer metastasis
and acts as a tumor suppressor. Liu et al. found that
transplantation of BCL11A-knockout murine fetal liver
cells resulted in T-cell leukemia in recipient mice,
suggesting that BCL11A may be a non–cell autonomous
T-cell tumor suppressor gene [6]. Moreover, another
member of the BCL11 family, BCL11B, has been suggested
as a tumor suppressor gene, acting via an increase in
resistance to DNA damage [25,26]. In addition to the po-
tential mechanism mentioned above, two cell cycle check-
point members, P21 and CHEK1, which contribute to
several cell cycle checkpoints, including the G1/S and G2/
Figure 4 BCL11A gene amplification is frequently observed in squamous cell carcinoma. (A) Chromosome and gene views of copy
number variance (CNV) signals in NSCLC with different histological origins. Log2 ratios of CNV probe intensity are plotted on the x axis against
genomic location on the y axis. The blue horizontal line represents the location of the BCL11A gene on chromosome 2. a, b, and c represent the
chromosome views of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, respectively. d, e, and f represent the gene views of
squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, respectively, which show a zoom-in view of BCL11A copy number variation
on the 2p16.1 band. (B) Expression levels were compared between SCC samples without high copy number amplification (SCC-) and SCC with
high copy number amplification (SCC+) of the genomic region harboring the gene of interest.
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Figure 5 Computationally predicted miRNAs targeting BCL11A are downregulated in NSCLC tissues. (A) Schematic of three different
binding sites in the BCL11A 3′UTR complementary to the “seed region” of three miRNAs, including miR-135a, miR-1, and miR-30a. (B) miR-1 and
miR-30a were downregulated in NSCLC tissues compared to adjacent lung tissues (n = 22).
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tion of P21 and CHEK1 can promote DNA repair,
maintain genomic integrity, and attenuate chemo- or
radiotherapeutic efficacy [27,28]. Collective evidence sug-
gests that P21 and CHEK1 could be targets of BCL11A.
This interesting phenomenon implied BCL11A might
have a dual role during NSCLC progression. In the initi-
ation of tumorigenesis, BCL11A might act as an oncogene
by repressing P21, CHEK1, and P53, resulting in genomic
instability and contributing to carcinogenesis. However,
once the tumor is established, BCL11A might inhibit can-
cer metastasis and improve the sensitivity of chemo- or
radiotherapy, thereby contributing to better survival. This
hypothesis should be further investigated in future studies.
There were several mechanisms that accounted for the
abnormal activation of the proto-oncogene BCL11A
reported in malignant hematological disease, including
genomic amplification, chromosomal translocation, and
retroviral integration. In this study, BCL11A gene copy
number gains were frequently observed in squamous cell
lung cancer patients, but not in adenocarcinoma or large
cell carcinoma patients, which matched the results of
Boelens et al. They observed that about 12% of squamous
cell lung cancers had high copy number amplifications on
chromosomal regions 2p15–p16.1, In addition, a signifi-
cantly higher average expression level was observed for
BCL11A in the SCC samples with amplifications ascompared to SCC without amplifications. Combined re-
sults demonstrated that genomic amplification is partially
responsible for abnormal BCL11A expression in SCC tis-
sues. MicroRNAs are approximately 21-nucleotide-long
RNA regulators of gene expression at the translational
level and control gene expression post-transcriptionally by
regulating mRNA translation in the cytoplasm [29,30].
Using the miRGen database [14], we found that BCL11A
is a common target of miR-1 and miR-30a, which were
downregulated in NSCLC compared to normal lung tis-
sues. Thus, we performed miRNA transfection to explore
whether downregulation of miRNAs in NSCLC tissues
contributed to deregulation of BCL11A. The results dem-
onstrated that miR-30a could inhibit BCL11A protein ex-
pression in vitro. Thus, inactivation of miR-30a might also
contribute to proto-oncogene BCL11A activation. How-
ever, whether these two mechanisms act synergistically re-
mains unknown. In addition, we did not elucidate the
biological functions of BCL11A and miR-30a in NSCLC.
In summary, we report here for the first time the
potential role of BCL11A in diagnosing and predicting
the prognosis of patients with NSCLC, especially those
with early stage lung squamous carcinoma. BCL11A
was highly and specifically expressed in cancer tissues
rather than adjacent non-cancerous tissues. Deregulated
expression of BCL11A might be partly caused by miR-
30a inactivation and genomic BCL11A amplification.
Figure 6 The BCL11A 3′-UTR is the target of miR-30a, but not of miR-1. pmirGLO-BCL11A luciferase constructs, containing a wild-type or
mutated BCL11A 3′-UTR (A), were transfected into A549 cells with (B) miR-30a, (C) miR-1, or control miRNA vectors. Relative repression of firefly
luciferase expression was standardized to Renilla luciferase activity. The reporter assays were performed three times with essentially identical
results. The P value was calculated comparing control microRNA and miR-30a or miR-1. (D) miR-30a downregulated BCL11A protein expression in
H520 cells. Control miRNAs were also used for transfection. The experiment was performed three independent times, and representative results
are displayed. CD511B represents the pCDH-CMV-MCS-EF1-copGFP empty vector. (E) Immunofluorescence staining intensity of BCL11A protein in
H460 cells observed by confocal microscopy after transfection with miR-30a or control miRNA. Magnification, ×200.
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functions as an oncogene or tumor suppressor gene in
NSCLC, whether BCL11A can be a better diagnostic
and prognostic biomarker of early stage squamous cell
lung cancer.
Conclusions
Activation of the proto-oncogene BCL11A may be a po-
tential diagnostic and prognostic biomarker of NSCLC,
and is modulated by miR-30a and gene amplification.Methods
Patients and tissue samples
Surgical specimens were obtained with informed consent
from 114 NSCLC patients (81 males and 33 females) who
underwent potentially curative surgery at Guangdong
General Hospital between 2003 and 2006. This study
was approved by the Institutional Review Board (IRB) of
Guangdong General Hospital. The staging and histo-
logical classifications were based on the World Health
Organization (WHO) system. A follow-up evaluation
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col. The median follow-up period was 47.2 months
(range, 3.1–75.2 months). Hemotoxylin and eosin
(H&E) staining was performed on sections of each tissue
to determine the percentage of tumor cells by two inde-
pendent pathologists. Only those samples with tumor
content ≥ 80% were allowed to enter this study. Demo-
graphic and clinical characteristics of the patients are
listed in Additional file 2: Table S1.
Cell lines
The NIH3T3, A549,NCI-H460 and H520 cell lines were
obtained from the American Type Culture Collection
(Manassas, VA, USA) and were cultured in RPMI 1640
medium (Invitrogen, Carlsbad, CA) supplemented with
10% fetal bovine serum (Thermo, Waltham, MA). Cells
were maintained at 37°C in a humidified 5% CO2
incubator (Thermo).
Gene expression profiling using Affymetrix GeneChip®
technology
Cancer tissue samples from 114 cases and 53 adjacent
non-tumor tissue samples were subject to gene profiling
tests using the Affymetrix human genome U133 plus 2.0
GeneChip® (Affymetrix, Santa Clara, CA, USA). Agilent
GeneSpring® software (Agilent Technologies, Santa
Clara, CA, USA) was utilized for the analysis of differ-
entially expressed genes between cancerous and adja-
cent non-cancerous tissues with a Bonferroni correction
FDR (false discovery rate) of 0.0001. Normalized
intensities of Affymetrix probe sets targeting BCL11A
(222891_s_at, 219497_s_at, 219498_s_at, 1559078_s_at,
and 210347_s_at) were extracted and averaged for plot-
ting across all samples.
Immunohistochemistry on tissue microarrays
Tissue microarrays were constructed using a manually
operated tissue arrayer (Beecher Instruments, Sun Prairie,
WI, USA). A total of 113 formaldehyde-fixed paraffin-
embedded (FFPE) samples were successfully used to gener-
ate four serial tissue arrays. Immunohistochemical staining
process was performed according to the protocol provided
by DAKO (DakoCytomation, Glostrup, Denmark) [31]. A
primary mouse monoclonal antibody against human
BCL11A (ab19487; Abcam, Cambridge, USA) was applied
to the sections at a dilution of 1:200 for 1 h at room
temperature. The sections were counterstained with
Harris’s hematoxylin. Each tumor was assigned a score
according to the intensity of the nucleic or cytoplasmic
staining (0 = no staining , 1 = weak staining, 2 =moderate
staining, and 3 = strong staining) and the proportion of
stained tumor cells (0 = 0%, 1 = 1–10%, 2 = 11–50% , 3 =
51–80%, and 4 = 81–100%) [31], as judged by two patholo-
gists, independently. The final immunoreactive score wasdetermined by multiplying the intensity scores by the
extent of positivity scores of stained cells, with a minimum
score of 0 and a maximum score of 12. Tumors with
scores ≥ 6 were classified into the high BCL11A expression
group, while the others were classified into the low
BCL11A expression group.
Array-based comparative genome hybridization (aCGH)
analysis
Array-CGH tests were performed using the Agilent Hu-
man Genome Microarray kit 244A (Agilent Technologies).
Labeling and hybridization were performed according to
the protocol provided by Agilent (Protocol v4.0, June
2006). Ten probes targeting BCL11A on the Agilent
aCGH chip (A_16_P15674055, A_16_P15674092, A_16_
P00386506, A_14_P202460, A_16_P15674199, A_14_P12
9011, A_16_P15674243, A_16_P00386603, A_16_P0038
6649, and A_14_P106886) were used to determine the
normalized logarithmic intensity of BCL11A copy number
changes. Log intensities > 0.30 were considered to indicate
gene amplification.
BCL11A-targeting microRNA prediction
To identify miRNAs targeting BCL11A, we integrated
the output results from the DIANA miRGen online
database, which were generated using multiple predic-
tion programs: TargetScan [http://www.targetscan.org/],
PicTar [http://www.pictar.org/], miRanda [http://www.
microrna.org/microrna/] and DIANA microT [http://
diana.pcbi.upenn.edu/cgi-bin/micro_t.cgi] [14]. We inte-
grated the results for each prediction tool and exported
the sequences of predicted binding sites for each
microRNA in the BCL11A 3′UTR.
Quantification of microRNA expression using real time
qRT-PCR
Twenty-two paired NSCLC tissues undergoing microRNA
analyses included (nine cases of adenocarcinoma, eight of
squamous cell carcinoma, and five of large cell carcinoma)
were subjected to microRNA analyses. Quantitative RT-
PCR amplification of microRNA and RNU6 was performed
using the pre-developed Assay-on-Demand Gene Expres-
sion Set for the microRNA (Applied Biosystems, Foster
City, CA). Briefly, 10 ng of total RNA was reverse tran-
scribed into cDNA using High Capacity cDNA sysnthesis
kit (Applied Biosystems) in the presence of stem-loop
primers. All reactions were performed in triplicates using
20 μl samples containing 1 ng of cDNA. The qRT-PCR
reaction was performed using in an ABI PRISM 7500FAST
system (Applied Biosystems), with the following cycling
conditions: 10 min at 95°C, and 40 cycles of 95°C for
15 s and 60°C for 60 s. microRNA expression was quan-
tified using the comparative CT (cycle at threshold)
method, which normalizes the CT values to an internal
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MicroRNA vectors and luciferase reporter assays
Two microRNA-expressing plasmids were constructed.
DNA fragments carrying pre-microRNAs were ampli-
fied by high-fidelity PCR using genomic DNA from a
healthy blood donor as a template. PCR reactions were
performed using the high-fidelity Phusion polymerase
(New England Biolabs), and specific primers ending
with sequences for EcoRI and NotI enzymes (New
England Biolabs) (Additional file 3: Table S2). The
amplified fragment was enzyme digested and subsequently
cloned into pCDH-CMV-MCS-EF1-copGFP (System Bio-
sciences, Mountain View, CA) at the EcoRI and NotI sites.
Expression of the mature microRNAs was verified by
TaqMan real-time qRT-PCR. Luciferase constructs were
created by ligating oligonucleotides (Additional file 4:
Table S3) containing the wild type or mutant target site of
the BCL11A 3-UTR into the DraI and XbaI sites of the
pmirGLO vector (Promega, Madison, WI). Vectors were
sequenced using an EBV reverse primer: 5′-GTGGTTT
GTCCAAACTCATC-3′. A549 and NIH3T3 cells (low en-
dogenous BCL11A expression; data not shown) were co-
transfected with 0.5 μg of pmirGLO luciferase reporter
vector containing a wild type or mutant target site and
0.5 μg of the microRNA plasmid using Lipofectamine™
LTX reagent (Invitrogen, Carlsbad) in 12-well plates.
After incubation for 48 h, the cells were lysed and lucif-
erase assays were conducted using a GloMax™ 20/20
Luminometer (Promega). Firefly luciferase activity was
normalized to Renilla luciferase activity. Each experi-
ment was performed in triplicate [32].
Western blotting
H520 cells (high endogenous BCL11A expression; data
not shown) were transfected with the control microRNA-
or miR-30a-expressing vector. Approximately 48 h after
transfection, the cells were lysed. Western blotting was
performed as described previously [33]. The anti-BCL11A
antibody (ab19487) was obtained from Abcam and was
used at a dilution of 1:1,000.
Visualization of intracellular BCL11A protein expression
by confocal microscopy
Indirect immunofluorescence staining was used to deter-
mine BCL11A expression in miR-30a-transfected cells as
described previously [34]. Briefly, H460 cells (high en-
dogenous BCL11A expression; data not shown) were
transfected with the control microRNA- or miR-30a-ex-
pressing vector, and 48 h after transfection, the cells
were fixed with cold methanol. A primary antibody
against BCL11A (ab19487; Abcam) was applied at a dilu-
tion of 1:100, followed by a secondary antibody conjugatedto Alexa Fluor 635 (Invitrogen). DAPI (Invitrogen) was
used as a nuclear stain, and GFP was used to monitor
transfection efficiency.Statistical analysis
Statistical significance was determined by paired or un-
paired Student’s t-tests in cases of standardized expres-
sion data. One-way analysis of variance (ANOVA) was
performed for comparisons of multiple groups using the
GraphPad Prism Software 5.01 (GraphPad, La Jolla, CA).
Wilcoxon matched-pair tests and Mann-Whitney U tests
were used for nonparametric analysis of non-Gaussian
data. Error bars represent standard deviations (± SD).
Chi-square tests and McNemar’s tests were used to
assess the association of BCL11A level with clinical
variables. Survival curves between subgroups divided
according to BCL11A expression level were drawn using
the Kaplan-Meier method, and significant differences
among subgroups were compared by log-rank test. A
multivariate analysis was performed using the stepwise
method. Hazards ratios and 95% confidence intervals
were calculated using Cox proportional hazards models.
P values < 0.05 were considered statistically significant.Additional files
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